INTERACTIONS OF FLUOROQUINOLONES WITH OTHER DRUGS - MECHANISMS, VARIABILITY, CLINICAL-SIGNIFICANCE, AND MANAGEMENT

被引:79
作者
RADANDT, JM [1 ]
MARCHBANKS, CR [1 ]
DUDLEY, MN [1 ]
机构
[1] UNIV RHODE ISL, COLL PHARM,ROGER WILLIAMS MED CTR, ANTIINFECT PHARMACOL RES UNIT,5TH FLOOR, PROVIDENCE, RI 02908 USA
关键词
D O I
10.1093/clinids/14.1.272
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Several important interactions of fluoroquinolones with other drugs have been reported in the literature. The absorption of all fluoroquinolones is almost entirely inhibited by concomitant administration of di- and trivalent cations, such as aluminum and magnesium contained in antacids. The inhibition of absorption can be significant and can potentially lead to the failure of treatment, even when fluoroquinolone doses are separated from antacid doses by hours. Certain isozymes of the cytochrome P-450 system are selectively inhibited by some fluoroquinolones. The metabolism of theophylline and caffeine is inhibited by enoxacin and ciprofloxacin such that the dosage of theophylline may need to be reduced in order to avoid toxicity. In contrast, ofloxacin and norfloxacin cause less inhibition of the metabolism of these compounds, and reduction of the theophylline dosage is not routinely required. Evidence regarding the effect of fluoroquinolones on the disposition of other drugs known to be metabolized, such as warfarin and cyclosporine, is inconclusive. In summary, the safe and effective use of fluoroquinolone antibiotics requires careful consideration of concomitant drug therapy.
引用
收藏
页码:272 / 284
页数:13
相关论文
共 100 条
  • [1] SYNERGISTIC NEPHROTOXICITY DUE TO CIPROFLOXACIN AND CYCLOSPORINE
    AVENT, CK
    KRINSKY, D
    KIRKLIN, JK
    BOURGE, RC
    FIGG, WD
    [J]. AMERICAN JOURNAL OF MEDICINE, 1988, 85 (03) : 452 - 453
  • [2] ALTERATION IN THE PHARMACOKINETIC DISPOSITION OF CIPROFLOXACIN BY SIMULTANEOUS ADMINISTRATION OF AZLOCILLIN
    BARRIERE, SL
    CATLIN, DH
    ORLANDO, PL
    NOE, A
    FROST, RW
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (05) : 823 - 826
  • [3] ENHANCED ELIMINATION OF CIPROFLOXACIN AFTER MULTIPLE-DOSE ADMINISTRATION OF RIFAMPIN TO RABBITS
    BARRIERE, SL
    KAATZ, GW
    SEO, SM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (04) : 589 - 590
  • [4] ENOXACIN - A POTENT INHIBITOR OF THEOPHYLLINE METABOLISM
    BECKMANN, J
    ELSASSER, W
    GUNDERTREMY, U
    HERTRAMPF, R
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 33 (03) : 227 - 230
  • [5] DANGER OF INTERACTION BETWEEN CIPROFLOXACIN AND THEOPHYLLINE
    BEM, JL
    MANN, RD
    [J]. BRITISH MEDICAL JOURNAL, 1988, 296 (6629) : 1131 - 1131
  • [6] EFFECT OF NORFLOXACIN ON THEOPHYLLINE PHARMACOKINETICS AT STEADY-STATE
    BOWLES, SK
    POPOVSKI, Z
    RYBAK, MJ
    BECKMAN, HB
    EDWARDS, DJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (04) : 510 - 512
  • [7] EFFECT OF QUINOLONES ON CAFFEINE DISPOSITION
    CARBO, ML
    SEGURA, J
    DELATORRE, R
    BADENAS, JM
    CAMI, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (03) : 234 - 240
  • [8] MULTIPLE-DOSE PHARMACOKINETICS OF CONCURRENT ORAL CIPROFLOXACIN AND RIFAMPIN THERAPY IN ELDERLY PATIENTS
    CHANDLER, MHH
    TOLER, SM
    RAPP, RP
    MUDER, RR
    KORVICK, JA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (03) : 442 - 447
  • [9] OVERVIEW OF DRUG-INTERACTIONS WITH THE QUINOLONES
    DAVEY, PG
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 : 97 - 107
  • [10] DAVIES BI, 1989, REV INFECT DIS, V11, pS1083